Risks of Testosterone for Postmenopausal Women.

Androgens Female Hormone Replacement Therapy / adverse effects Humans Male Postmenopause Sexual Dysfunctions, Psychological / drug therapy Testosterone / adverse effects
Androgen Genitourinary syndrome of menopause Hypoactive sexual desire disorder Menopause Risks Safety Testosterone Women

Journal

Endocrinology and metabolism clinics of North America
ISSN: 1558-4410
Titre abrégé: Endocrinol Metab Clin North Am
Pays: United States
ID NLM: 8800104

Informations de publication

Date de publication:
03 2021
Historique:
entrez: 1 2 2021
pubmed: 2 2 2021
medline: 26 10 2021
Statut: ppublish

Résumé

Transdermal testosterone therapy, dosed within premenopausal physiologic testosterone ranges, used alone or with menopausal hormone therapy for postmenopausal hypoactive sexual desire disorder, has shown short-term efficacy, with few androgenic side effects. After natural or surgical menopause, meaningful improvements include an additional satisfying sexual episode per month; improvement in desire, arousal, orgasm, pleasure, and responsiveness; and a reduction in distress. Long-term data on cardiovascular, cancer, and cognitive safety are lacking. No approved testosterone preparation is available for women. Compounded testosterone creams or reduced dosing of male-approved therapies represent off-label use. Injections or pellets cause supraphysiological testosterone levels and are not recommended.

Identifiants

DOI: 10.1016/j.ecl.2020.10.007 PMID: 33518182
pubmed: 33518182
pii: S0889-8529(20)30085-2
doi: 10.1016/j.ecl.2020.10.007
pii:
doi:

Substances chimiques

Androgens 0
Testosterone 3XMK78S47O

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

139-150

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Disclosure J.V. Pinkerton—none in past 24 months. I. Blackman—no disclosures. E.A. Conner—no disclosures. A.M. Kaunitz: Advisory Boards: Mithra, Pfizer; Clinical trials (financial support to University of Florida): Mithra.

Auteurs

JoAnn V Pinkerton (JV)

Department of Obstetrics and Gynecology, Division of Midlife Health, University of Virginia Health System, Midlife Health Center University of Virginia Health System, PO Box 801104, Charlottesville, VA 22908, USA. Electronic address: jvp9u@virginia.edu.

Isabella Blackman (I)

Department of Obstetrics and Gynecology, Division of Midlife Health, University of Virginia Health System, Midlife Health Center University of Virginia Health System, PO Box 801104, Charlottesville, VA 22908, USA.

Edward Alexander Conner (EA)

Department of Obstetrics and Gynecology, Division of Midlife Health, University of Virginia Health System, Midlife Health Center University of Virginia Health System, PO Box 801104, Charlottesville, VA 22908, USA.

Andrew M Kaunitz (AM)

University of Florida College of Medicine Jacksonville, UF Health Women's Specialists, Building 2, Suite 20, 4549 Emerson Street, Jacksonville, FL 32207, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Hormones, substituts d'hormones et antagonistes d'hormones › Hormones › Androgènes › Risks of Testosterone for Postmenopausal Women.
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Hormonothérapie substitutive › Risks of Testosterone for Postmenopausal Women.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Risks of Testosterone for Postmenopausal Women.
questionsmedicales.fr › Phénomènes physiologiques des appareils urinaire et reproducteur › Phénomènes physiologiques de la reproduction › Développement sexuel › Climatère › Ménopause › Post-ménopause › Risks of Testosterone for Postmenopausal Women.
questionsmedicales.fr › Troubles mentaux › Dysfonctionnements sexuels psychogènes › Risks of Testosterone for Postmenopausal Women.
questionsmedicales.fr › Hormones gonadiques › Hormones sexuelles stéroïdiennes › Congénères de la testostérone › Testostérone › Risks of Testosterone for Postmenopausal Women.